HomeHome

Bone Health History in Breast Cancer Patients on Aromatase Inhibitors

Marilyn L. Kwan; Joan C. Lo; Li Tang; Cecile A. Laurent; Janise M. Roh; Malini Chandra; Theresa E. Hahn; Chi-Chen Hong; Lara Sucheston-Campbell; Dawn L. Hershman; Charles P. Quesenberry Jr.; Christine B. Ambrosone; Lawrence H. Kushi; Song Yao

Title:
Bone Health History in Breast Cancer Patients on Aromatase Inhibitors
Author(s):
Kwan, Marilyn L.
Lo, Joan C.
Tang, Li
Laurent, Cecile A.
Roh, Janise M.
Chandra, Malini
Hahn, Theresa E.
Hong, Chi-Chen
Sucheston-Campbell, Lara
Hershman, Dawn L.
Quesenberry Jr., Charles P.
Ambrosone, Christine B.
Kushi, Lawrence H.
Yao, Song
Date:
Type:
Articles
Department(s):
Medicine
Volume:
9
Persistent URL:
Book/Journal Title:
PLoS ONE
Publisher:
Public Library of Science
Abstract:
A cross-sectional study was performed to assess bone health history among aromatase inhibitor (AI) users before breast cancer (BC) diagnosis, which may impact fracture risk after AI therapy and choice of initial hormonal therapy. A total of 2,157 invasive BC patients initially treated with an AI were identified from a prospective cohort study at Kaiser Permanente Northern California (KPNC). Data on demographic and lifestyle factors were obtained from in-person interviews, and bone health history and clinical data from KPNC clinical databases. The prevalence of osteoporosis and fractures in postmenopausal AI users was assessed, compared with 325 postmenopausal TAM users. The associations of bone health history with demographic and lifestyle factors in AI users were also examined. Among all initial AI users, 11.2% had a prior history of osteoporosis, 16.3% had a prior history of any fracture, and 4.6% had a prior history of major fracture. Postmenopausal women who were taking TAM as their initial hormonal therapy had significantly higher prevalence of prior osteoporosis than postmenopausal AI users (21.5% vs. 11.8%, p<0.0001). Among initial AI users, the associations of history of osteoporosis and fracture in BC patients with demographic and lifestyle factors were, in general, consistent with those known in healthy older women. This study is one of the first to characterize AI users and risk factors for bone morbidity before BC diagnosis. In the future, this study will examine lifestyle, molecular, and genetic risk factors for AI-induced fractures.
Subject(s):
Osteoporosis
Breast--Cancer--Patients
Aromatase
Oncology
Epidemiology
Medicine
Publisher DOI:
https://doi.org/10.1371/journal.pone.0111477
Item views
311
Metadata:
text | xml
Suggested Citation:
Marilyn L. Kwan, Joan C. Lo, Li Tang, Cecile A. Laurent, Janise M. Roh, Malini Chandra, Theresa E. Hahn, Chi-Chen Hong, Lara Sucheston-Campbell, Dawn L. Hershman, Charles P. Quesenberry Jr., Christine B. Ambrosone, Lawrence H. Kushi, Song Yao, , Bone Health History in Breast Cancer Patients on Aromatase Inhibitors, Columbia University Academic Commons, .

Columbia University Libraries | Policies | FAQ